Clinical Trials Sponsored by Clarity Pharmaceuticals Ltd

Total 4479 results

Idorsia Pharmaceuticals Ltd.

Completed

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

Healthy

Portugal
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
BioMarck Pharmaceuticals, Ltd.

Completed

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

Respiratory Distress Syndrome, Adult

United States
BioMarck Pharmaceuticals, Ltd.

Completed

A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB

India
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Spain, Hungary, Israel, Sweden
Atlantic Pharmaceuticals Ltd

Completed

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Pouchitis

United States, Belgium, Canada, France, Ireland, Israel, Italy, Netherlands, Switzerland, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men

Healthy Subjects

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

Obstructive Sleep Apnea

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Healthy Subjects

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients

Photosensitive Epilepsy

France, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Terminated

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Healthy Subjects

France
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

Healthy Subjects

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

France
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

Fabry Disease

Germany
Idorsia Pharmaceuticals Ltd.

Terminated

Clazosentan in Aneurysmal Subarachnoid Hemorrhage (CONSCIOUS-3)

Aneurysmal Subarachnoid Hemorrhage

United States, Belgium, Taiwan, Canada, Hong Kong, Singapore, Germany, Netherlands, India, Czechia, Switzerland, France, Australia, Spain, Denmark, Finland, Argentina, Brazil, Sweden, Austria, Chile, Hungary, Israel, Italy, Mexico, Norway, ... and more
Idorsia Pharmaceuticals Ltd.

Terminated

Tezosentan in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Japan, France
Neurim Pharmaceuticals Ltd.

Completed

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Sleep Problems

Netherlands
Sauflon Pharmaceuticals Ltd

Completed

Clinical Study of Visibility Tinted Clariti Contact Lens

Myopia | Hyperopia

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia

Insomnia

France
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Blindness | Non-24 Hour Sleep-Wake Disorder

United States
Neurim Pharmaceuticals Ltd.

Completed

A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia

Diabetes Mellitus, Type 2 | Insomnia
Targia Pharmaceuticals Ltd.
SoluBest Ltd.

Unknown

Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers

Migraine
Foresee Pharmaceuticals Co., Ltd.
QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Puberty; Precocious, Central

United States, China, Taiwan, Puerto Rico
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
Ono Pharmaceutical Co. Ltd
Kyorin Pharmaceutical Co.,Ltd

Completed

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Overactive Bladder

Japan
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Prostate Cancer

Korea, Republic of
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

Prostate Cancer

Korea, Republic of
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Persica Pharmaceuticals Ltd
Micron Research Ltd

Active, not recruiting

Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain

Chronic Low-back Pain

Spain, United Kingdom, New Zealand, Denmark
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (ANASSA-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece

3

Subscribe